We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00099697
Recruitment Status : Completed
First Posted : December 20, 2004
Last Update Posted : December 11, 2009
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine whether DHEA replacement therapy decreases abdominal fat and improves insulin sensitivity.

Condition or disease Intervention/treatment
Aging Obesity Insulin Resistance Drug: DHEA

Detailed Description:

Studies on rats and mice have shown that the adrenal hormone dehydroepiandrosterone (DHEA) reduces abdominal visceral fat and protects against insulin resistance. This study was done to learn if DHEA replacement therapy decreases abdominal obesity and improves insulin action in humans.

Participants were randomly assigned to receive 50 mg per day of DHEA or a placebo at bedtime for 6 months. Participants underwent magnetic resonance imaging (MRI) and oral glucose tolerance tests at the beginning and conclusion of the study. Other tests included measurements of hormones and lipids.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Masking: Double
Primary Purpose: Prevention
Official Title: Biologic Effects of DHEA in Humans
Study Start Date : June 2001
Primary Completion Date : February 2004
Study Completion Date : February 2004
Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. 6-month change in visceral and subcutaneous abdominal fat

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years to 78 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 65 to 78 years old
  • Physically healthy
  • Non-smoker
  • On stable medications for at least 6 months
  • Stable body weight for the past year

Exclusion Criteria:

  • Serious active medical problems
  • Hormone therapy
  • Abnormal PSA (prostate specific antigen) in men
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099697

United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
National Institute on Aging (NIA)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Research Resources (NCRR)
Principal Investigator: John O. Holloszy, MD Washington University School of Medicine
Principal Investigator: Dennis T. Villareal, MD Washington University School of Medicine
More Information

ClinicalTrials.gov Identifier: NCT00099697     History of Changes
Other Study ID Numbers: AG0013
5P60AG013629 ( U.S. NIH Grant/Contract )
5R01AG020076 ( U.S. NIH Grant/Contract )
5K23RR016191 ( U.S. NIH Grant/Contract )
3P30DK056341 ( U.S. NIH Grant/Contract )
5P60DK020579 ( U.S. NIH Grant/Contract )
2M01RR000036 ( U.S. NIH Grant/Contract )
First Posted: December 20, 2004    Key Record Dates
Last Update Posted: December 11, 2009
Last Verified: December 2004

Keywords provided by National Institute on Aging (NIA):
abdominal fat
Insulin sensitivity

Additional relevant MeSH terms:
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs